Shares of Assembly Biosciences Inc (NASDAQ:ASMB) have been given an average recommendation of “Hold” by the eight analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $53.67.
A number of analysts recently weighed in on ASMB shares. Chardan Capital restated a “hold” rating on shares of Assembly Biosciences in a research note on Sunday, June 30th. William Blair restated a “buy” rating on shares of Assembly Biosciences in a research note on Tuesday. Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th. Finally, BidaskClub lowered shares of Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a research note on Monday, June 24th.
Institutional investors have recently made changes to their positions in the business. BlackRock Inc. boosted its stake in Assembly Biosciences by 3.4% during the 4th quarter. BlackRock Inc. now owns 1,909,510 shares of the biopharmaceutical company’s stock valued at $43,193,000 after purchasing an additional 63,554 shares during the period. RTW Investments LP bought a new stake in Assembly Biosciences during the 4th quarter valued at approximately $15,532,000. Victory Capital Management Inc. boosted its stake in Assembly Biosciences by 5.9% during the 1st quarter. Victory Capital Management Inc. now owns 562,399 shares of the biopharmaceutical company’s stock valued at $11,074,000 after purchasing an additional 31,490 shares during the period. Emerald Advisers LLC boosted its stake in Assembly Biosciences by 20.3% during the 1st quarter. Emerald Advisers LLC now owns 468,379 shares of the biopharmaceutical company’s stock valued at $9,222,000 after purchasing an additional 79,039 shares during the period. Finally, FMR LLC lifted its position in shares of Assembly Biosciences by 0.6% in the 1st quarter. FMR LLC now owns 445,716 shares of the biopharmaceutical company’s stock worth $8,776,000 after acquiring an additional 2,680 shares during the period. Institutional investors own 86.44% of the company’s stock.
Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.06) by $0.01. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. The firm had revenue of $3.89 million for the quarter, compared to analyst estimates of $3.81 million. As a group, research analysts predict that Assembly Biosciences will post -4.34 EPS for the current year.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Featured Article: How Investors Use a Balance Sheet
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.